117 related articles for article (PubMed ID: 34404077)
1. [A Case of Pseudopancreatic Cyst Development during Bevacizumab plus Paclitaxel Therapy for Pancreatic Metastasis of Breast Cancer].
Shiina N; Fujisaki K; Miyoshi T; Yokomizo J; Sai G; Wakabayashi Y; Ootsubo Y
Gan To Kagaku Ryoho; 2021 Aug; 48(8):1061-1063. PubMed ID: 34404077
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
[TBL] [Abstract][Full Text] [Related]
4. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Martin M; Roche H; Pinter T; Crown J; Kennedy MJ; Provencher L; Priou F; Eiermann W; Adrover E; Lang I; Ramos M; Latreille J; Jagiełło-Gruszfeld A; Pienkowski T; Alba E; Snyder R; Almel S; Rolski J; Munoz M; Moroose R; Hurvitz S; Baños A; Adewoye H; Hei YJ; Lindsay MA; Rupin M; Cabaribere D; Lemmerick Y; Mackey JR;
Lancet Oncol; 2011 Apr; 12(4):369-76. PubMed ID: 21429799
[TBL] [Abstract][Full Text] [Related]
5. A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.
Puglisi F; Bisagni G; Ciccarese M; Fontanella C; Gamucci T; Leo L; Molino A; Silva RR; Marchetti P
Future Oncol; 2016 Nov; 12(22):2589-2602. PubMed ID: 27443691
[TBL] [Abstract][Full Text] [Related]
6. [A Case of Chemotherapy with Low-Dose Paclitaxel and Bevacizumab for Elderly Recurrent Breast Cancer Patient].
Munemoto M; Kano S; Ishikawa S; Makita N; Yagi Y; Oonishi I; Kayahara M
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2038-2040. PubMed ID: 33468793
[TBL] [Abstract][Full Text] [Related]
7. [Combination Therapy of Bevacizumab plus Paclitaxel Was Effective for a Metastatic Choroidal Tumor Secondary to Breast Cancer in a Patient with Ocular Symptoms].
Hattori M; Shirahane K; Sakai M; Sassa Y; Nishihara Y; Aibe H; Masuda M; Mori D
Gan To Kagaku Ryoho; 2020 Aug; 47(8):1221-1224. PubMed ID: 32829359
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
9. [A case of bone marrow carcinomatosis with disseminated intravascular coagulation arising from breast cancer successfully treated with paclitaxel plus bevacizumab].
Kawai H; Sugimoto R; Miyauchi S; Yoshida R; Waki N; Hirayama S; Ishizaki M; Nishi H; Yamashita K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1957-9. PubMed ID: 25731388
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
Miller K; Wang M; Gralow J; Dickler M; Cobleigh M; Perez EA; Shenkier T; Cella D; Davidson NE
N Engl J Med; 2007 Dec; 357(26):2666-76. PubMed ID: 18160686
[TBL] [Abstract][Full Text] [Related]
11. New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.
Cannita K; Paradisi S; Cocciolone V; Bafile A; Rinaldi L; Irelli A; Lanfiuti Baldi P; Zugaro L; Manetta R; Alesse E; Ricevuto E; Ficorella C
Cancer Med; 2016 Sep; 5(9):2232-9. PubMed ID: 27416882
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
Manso L; Palomo AG; Pérez Carrión R; Cassinello J; Gallegos Sancho I; Chacón López-Muñiz I; Olier C; Fernández-Aramburo A; Llorca C; González X; Llorente R; Torregrosa D; Álvarez I; Gálve E; Bueno C; Garau I; García MJ; González-Santiago S; Ballesteros AI; Blanco E; Galán A; González S; Perelló A; Cortés-Funes H; Grávalos C
Anticancer Res; 2015 Dec; 35(12):6941-50. PubMed ID: 26637920
[TBL] [Abstract][Full Text] [Related]
13. Acral cutaneous metastasis from a primary breast carcinoma following chemotherapy with bevacizumab and paclitaxel.
Armstrong P; Woody MM; Reichenberg JS; Gavino AC
Cutis; 2018 Sep; 102(3):E12-E14. PubMed ID: 30372726
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation.
Miles D; Cameron D; Bondarenko I; Manzyuk L; Alcedo JC; Lopez RI; Im SA; Canon JL; Shparyk Y; Yardley DA; Masuda N; Ro J; Denduluri N; Hubeaux S; Quah C; Bais C; O'Shaughnessy J
Eur J Cancer; 2017 Jan; 70():146-155. PubMed ID: 27817944
[TBL] [Abstract][Full Text] [Related]
15. Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Yamamoto Y; Yamashiro H; Toh U; Kondo N; Nakamura R; Kashiwaba M; Takahashi M; Tsugawa K; Ishikawa T; Nakayama T; Ohtani S; Takano T; Fujisawa T; Toyama T; Kawaguchi H; Mashino K; Tanino Y; Morita S; Toi M; Ohno S
Breast Cancer; 2021 Jan; 28(1):145-160. PubMed ID: 32715420
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].
Suzuki S; Sakurai K; Nagashima S; Hara Y; Amano S; Enomoto K; Makishima M
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1289-91. PubMed ID: 25335720
[TBL] [Abstract][Full Text] [Related]
17. Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Diéras V; Wildiers H; Jassem J; Dirix LY; Guastalla JP; Bono P; Hurvitz SA; Gonçalves A; Romieu G; Limentani SA; Jerusalem G; Lakshmaiah KC; Roché H; Sánchez-Rovira P; Pienkowski T; Seguí Palmer MÁ; Li A; Sun YN; Pickett CA; Slamon DJ
Breast; 2015 Jun; 24(3):182-90. PubMed ID: 25747197
[TBL] [Abstract][Full Text] [Related]
18. [A case of stage IV breast cancer with long-term partial response treated with tri-weekly paclitaxel plus bevacizumab].
Okamoto A; Nakatsukasa K; Fujita Y; Sugimoto R; Sakaguchi K; Taguchi T
Gan To Kagaku Ryoho; 2015 Mar; 42(3):343-6. PubMed ID: 25812504
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab
Nakamoto S; Watanabe J; Ohtani S; Morita S; Ikeda M
In Vivo; 2020; 34(3):1377-1386. PubMed ID: 32354934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
